Abstracts tagged "psoriasis"

Abstract Number: 16L • 2017 ACR/ARHP Annual Meeting
Incidence of Thromboembolic Events in the Tofacitinib Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis and Ulcerative Colitis Development Programs
Philip J Mease¹, Joel Kremer², Stanley Cohen³, Jeffrey R Curtis⁴, Christina Charles-Schoeman⁵, Edward V Loftus⁶, Jeffrey D Greenberg⁷, Niki Palmetto⁸, Keith S Kanik⁹, Daniela Graham⁹, Cunshan Wang⁹, Pinaki Biswas⁸, Gary Chan¹⁰, Ryan DeMasi¹⁰, Hernan Valdez⁸, Thijs Hendrikx¹⁰ and Thomas V Jones¹⁰, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ³Metroplex Clinical Research Center, Dallas, TX, ⁴University of Alabama, Birmingham, AL, ⁵University of California, Los Angeles, CA, ⁶Mayo Clinic, Rochester, MN, ⁷Corrona, LLC, Southborough, MA, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Groton, CT, ¹⁰Pfizer Inc, Collegeville, PA

Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor that preferentially inhibits signaling by JAK3 and JAK1, with functional selectivity over JAK2. Potential increased risk…
Abstract Number: 625 • 2017 ACR/ARHP Annual Meeting
Rapid Onset of Efficacy in Patients with Active Psoriatic Arthritis Treated with Ixekizumab: A Pooled Analysis of Data from Two Phase III Clinical Trials
Atul A. Deodhar¹, Kim A. Papp², Catherine Shuler³, So Young Park³ and Tore K. Kvien⁴, ¹Oregon Health & Science University, Portland, OR, ²K Papp Clinical Research and Probity Medical Research Inc, Waterloo, ON, Canada, ³Eli Lilly and Company, Indianapolis, IN, ⁴Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Rapid onset of clinical improvement is an important attribute of treatment success for patients with PsA. These analyses evaluate the speed of onset of…
Abstract Number: 639 • 2017 ACR/ARHP Annual Meeting
Clinical and Sonographic Analysis of Patients with Psoriasis without Musculoskeletal Complaints. Preeliminary Results of a Prospective Study: The PRE-Psa Cohort
Andrea Cuervo¹, Julio Ramírez², Merce Alsina³, Raimon Sanmarti⁴ and Juan D. Cañete⁵, ¹Arthritis Unit. Rheumatology Dpt, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ²Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ³Dermatology Dpt, Hospital Clinic de Barcelona, Barcelona, Spain, ⁴Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, ⁵Arthritis Unit. Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: Early diagnosis in psoriatic arthritis (PsA) is mandatory in order to initiate early therapy and prevent disability. Around 20% of patients with Psoriasis (PsO)…
Abstract Number: 882 • 2017 ACR/ARHP Annual Meeting
A New Model of Care for Improving Early Rheumatology Access of Psoriatic Arthritis Patients
Keith Colaco^1,2, Dana Jerome³, Jensen Yeung^4,5, Noah Ivers^6,7,8, Carol Kitai⁷, Chandra Farrer³ and Lihi Eder^1,9, ¹Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, ²Institute of Medical Science, University of Toronto, Toronto, ON, Canada, ³Rheumatology, Women's College Hospital, Toronto, ON, Canada, ⁴Dermatology, Women's College Hospital, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ⁷Women's College Hospital, Toronto, ON, Canada, ⁸Family and Community Medicine, University of Toronto, Toronto, ON, Canada, ⁹Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: The prevalence of undiagnosed psoriatic arthritis (PsA) in psoriasis patients is high, with delays in diagnosis contributing to poor patient outcomes. We aimed to…
Abstract Number: 989 • 2017 ACR/ARHP Annual Meeting
Impact of DMARD Treatment on Risk of Repeat Cardiovascular Events Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis
Jeffrey A. Sparks¹, Tamara Lesperance², Neil A. Accortt³ and Daniel H. Solomon⁴, ¹Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²DOCS Global, Inc., North Wales, PA, ³Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Chronic inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis (PsO) increase the risk of cardiovascular (CV) disease. However, it is…
Abstract Number: 1555 • 2017 ACR/ARHP Annual Meeting
Treatment Changes By Joint Activity and Skin Severity in Patients with Comorbid Psa and Pso
Philip J Mease¹, Carol J. Etzel², Jeffrey Lisse³, April W Armstrong⁴, William J Huster³, Sabrina Rebello², Rhiannon Dodge², Talia M Muram³, Sarah Al Sawah³, Mwangi J Murage³, Jeffrey D Greenberg² and William Malatestinic³, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keck School of Medicine, University of Southern California, Los Angeles, CA
Background/Purpose: Treatment of both joint and skin symptoms is important for overall disease management of patients with psoriatic arthritis and comorbid psoriasis1,2. The objective of…
Abstract Number: 1557 • 2017 ACR/ARHP Annual Meeting
Treatment Patterns in Psoriatic Arthritis: Experience from a Real-World Setting
Martin Brom¹, Sebastian Moyano¹, Florencia Beatriz Mollerach², Luciano Fernando Lo Giudice³, Maria Laura Acosta Felquer¹, Marina Scolnik⁴, Santiago Ruta⁴ and Enrique R Soriano⁵, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Rheumatology section, Internal Medicine Unit, Hospital Italiano de Buenos Aires and Fundacion PM Catoggio, CABA, Argentina, ⁴Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina, ⁵Argentina, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Both EULAR (European League Against Rheumatism) and GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) recently published treatment guidelines for Psoriatic…
Abstract Number: 2309 • 2017 ACR/ARHP Annual Meeting
Risk Factors for Arthritis and the Development of Comorbid Cardiovascular and Metabolic Disease in Children with Psoriasis
Cynthia K. Manos^1,2, Rui Xiao³, Timothy G. Brandon¹, Alexis Ogdie⁴ and Pamela F. Weiss^5,6, ¹Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, Philadelphia, PA, ³Department of Pediatrics, Division of Biostatistics, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Rheumatology, Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ⁶Department of Pediatrics, Perelman School of Medicine, Philadelphia, PA
Background/Purpose: Relatively little is known about the epidemiology of juvenile psoriatic arthritis (PsA), including risk factors for development of PsA among children with psoriasis. It…
Abstract Number: 2481 • 2017 ACR/ARHP Annual Meeting
Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients from Global Clinical Trials across Multiple Indications: An Updated Analysis in 29,987 Patients Representing 56,951 Patient-Years
Gerd R. Burmester¹, Remo Panaccione², Kenneth B. Gordon³, James T. Rosenbaum⁴, Dilek Arikan⁵, Winnie L. Lau⁵ and Rita Tarzynski-Potempa⁵, ¹Charité - University Medicine Berlin, Berlin, Germany, ²University of Calgary, Calgary, AB, Canada, ³Medical College of Wisconsin, Milwaukee, WI, ⁴Ophthalmology, Oregon Health & Science University and Legacy Devers Eye Institute, Portland, OR, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: Adalimumab is an anti–tumor necrosis factor-α (TNF-α) agent indicated for the treatment of immune-mediated diseases. The long-term safety of adalimumab was previously reported in…
Abstract Number: 2529 • 2017 ACR/ARHP Annual Meeting
Appraisal of the Contest Questionnaire in the Screening for Psoriatic Arthritis
Amir Haddad¹, Joy Feld^1,2, Lihi Eder³, Idit Lavi⁴, Oxana Zlazhover⁵ and Devy Zisman^1,6, ¹Rheumatology Unit Carmel Medical Center, Haifa, Israel, ²Rheumatology Unit, Carmel Medical Center, Haifa, Israel, ³Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, ⁴Epidemiology Unit Carmel Medical Center, Haifa, Israel, ⁵Bnei Zion Medical Center, Haifa, Israel, ⁶The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
Background/Purpose: Early diagnosis of psoriatic arthritis (PsA) is critical to prevent poor outcome. Several validated screening questionnaires have been developed to identify PsA patients in…
Abstract Number: 2531 • 2017 ACR/ARHP Annual Meeting
Utilization of the Psoriasis Epidemiology Screening Tool to Identify Signs and Symptoms of Early Psoriatic Arthritis Among Those with Psoriasis: Analysis from the Corrona Psoriasis Registry
Philip J Mease¹, Jacqueline B. Palmer², Mark Lebwohl³, Chitra Karki⁴, George W. Reed⁵, Carol J. Etzel⁶, Jeffrey D. Greenberg⁷ and Philip S. Helliwell⁸, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Corrona, LLC, Southborough, MA, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶The University of Texas MD Anderson Cancer Center, Houston, TX, ⁷New York University School of Medicine, New York, NY, ⁸School of Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: The Psoriasis Epidemiology Screening Tool (PEST) is a 5-item questionnaire developed to help identify psoriatic arthritis (PsA) at an early stage, with a score…
Abstract Number: 2532 • 2017 ACR/ARHP Annual Meeting
The Relationship between the Degree of Skin Involvement and Joint Activity in Patients with Psa: Experience from the Corrona Registry
Philip J Mease¹, Carol J. Etzel², Jeffrey Lisse³, April W Armstrong⁴, William J Huster³, Sabrina Rebello², Rhiannon Dodge², Talia M Muram³, Sarah Al Sawah³, Mwangi J Murage³, Jeffrey D Greenberg² and William Malatestinic³, ¹Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keck School of Medicine, University of Southern California, Los Angeles, CA
Background/Purpose: Prior studies have shown an inconsistent relationship between skin and joint symptoms in patients with comorbid PsO and PsA1-3. The objective of the…
Abstract Number: 2533 • 2017 ACR/ARHP Annual Meeting
Current Psa Therapy Impacts the Relationship between the Degree of Skin Invlovment and Joint Activity
Philip J Mease¹, Carol J. Etzel², Jeffrey Lisse³, April W Armstrong⁴, William J Huster³, Sabrina Rebello², Rhiannon Dodge², Talia M Muram³, Sarah Al Sawah³, Mwangi J Murage³, Jeffrey D Greenberg² and William Malatestinic³, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keck School of Medicine, University of Southern California, Los Angeles, CA
Background/Purpose: Simultaneous control of joint symptoms and degree of skin involvement has been linked to improvement in health-related quality of life in patients with coexistent…
Abstract Number: 2542 • 2017 ACR/ARHP Annual Meeting
Measuring Psoriasis Specific Impact on Quality of Life: Performance of Dlqi and Skindex-17 in Early Psoriatic Arthritis
Kim Wervers¹, Jolanda J. Luime², Ilja Tchetverikov³, Andreas H. Gerards⁴, Marc R Kok⁵, Cathelijne W. Y. Appels⁶, Wiebo L. van der Graaff⁷, Johannes H. L. M. van Groenendael⁸, Lindy-Anne Korswagen⁹, Jozien Veris¹⁰, J.M.W. Hazes² and Marijn Vis², ¹Erasmus Medical Centre, Rotterdam, Netherlands, ²Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, ³Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁴Sint Franciscus Vlietland Group, Schiedam, Netherlands, ⁵Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁶Rheumatology, Amphia Hospital, Breda, Netherlands, ⁷Rheumatology, Rivas hospital, Gorinchem, Netherlands, ⁸Rheumatology, Reumazorg Zuid West Nederland, Roosendaal, Netherlands, ⁹Sint Franciscus Vlietland Group, Rotterdam, Netherlands, ¹⁰Rheumatology, Reumazorg Zuid West Nederland, Goes, Netherlands
Background/Purpose: Impact of dermatological disease is measured with the Dermatology Life Quality Index (DLQI) and Skindex-17. DLQI is commonly used in dermatology trials but the…
Abstract Number: 2556 • 2017 ACR/ARHP Annual Meeting
Were Moll and Wright Right?
Sergio Schwartzman¹, Madeline Epsten², Jackie Szymonifka², Stephen A. Paget³ and Lisa A. Mandl¹, ¹Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Division of Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: In 1973 Moll and Wright published the first paper on the classification criteria for Psoriatic Arthritis (PsA). In their pioneering work, these authors additionally…

1
2
3
…
5
Next Page »